Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD

The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.

Celyad Announces Positive Data and Updates for CAR T Candidates

The phase 1b KEYNOTE-B79 trial of CYAD-101 for mCRC is expected to initiate in Q4 2021.

Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors

The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.

Future Research With Car T-Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.

Improving CAR Lymphoma Treatments With Epstein-Barr Virus T-Cell Therapy

Findings from an ongoing phase 1 trial were presented at the 2021 ASGCT meeting.

Making Antigen-Presenting Cells With Cell Squeeze Technology

The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.